Bevacizumab is a humanized anti-VEGF monoclonal antibody, which can inhibit tumor angiogenesis by binding with VEGFA and inhibiting its binding with vascular endothelial growth factor receptor (VEGFR)-2. The gene discussed is VEGFA; the disease is neoplasm.